Everolimus by Tandem Mass Spectrometry
Also known as: EVEROLIMUS
Use
Everolimus by Tandem Mass Spectrometry is utilized for therapeutic drug monitoring to optimize dosing and monitor patient adherence. It is FDA approved for organ rejection prophylaxis in adults receiving kidney and liver transplants under Zortress, and for renal cell carcinoma and SEGA associated with tuberous sclerosis under Afinitor. Therapeutic and toxic ranges differ based on patient-specific factors, medication combinations, and transplant specifics.
Special Instructions
Everolimus concentrations can be measured by chromatographic or immunoassay methodologies, which are not interchangeable. Consistency in using either method is vital due to variations in reference ranges. Immunoassays may show positive bias due to cross-reactivity with metabolites.
Limitations
Results may vary according to the specific methodology used for measurement; reference ranges differ between chromatographic and immunoassay techniques. Factors influencing therapeutic range include indication for therapy, treatment phase, concurrent drug therapies, timing of collection relative to dosing, type of transplant, and individual transplant center practices.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 50544-6
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
1 mL
Minimum Volume
0.25 mL
Container
Lavender (EDTA) or pink (K2EDTA)
Patient Preparation
Predose (trough) levels should be drawn
Storage Instructions
Refrigerated
Causes for Rejection
Serum or plasma. Specimens left at room temperature for longer than 24 hours. Clotted specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 2 weeks |
| Frozen | 2 weeks |